Australia markets closed

Aptorum Group Limited (APM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.4900-0.0100 (-0.40%)
As of 11:56AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.5000
Open2.5200
Bid2.4900 x 1000
Ask2.5100 x 1100
Day's range2.4654 - 2.5200
52-week range2.0000 - 4.9400
Volume21,013
Avg. volume137,218
Market cap88.711M
Beta (5Y monthly)-0.18
PE ratio (TTM)N/A
EPS (TTM)-0.1070
Earnings date15 Sept 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.00
  • Business Wire

    Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

    NEW YORK & LONDON & PARIS, October 19, 2021--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that it will hold its 2021 annual general meeting of shareholders at Meeting Room 06, 1/F, Building 1E, Hong Kong Science Park, N.T., Hong Kong at 8:00 p.m. Hong Kong Time on December 2, 2021 (7:00 a.m. Eastern Standa

  • Business Wire

    Aptorum Group Limited Interview to Air on Bloomberg U.S.

    NEW YORK & LONDON & PARIS, October 15, 2021--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, today announced that an interview with President Darren Lui will air on The RedChip Money Report® on Bloomberg TV Oct. 16 at 7 p.m. Eastern Time (ET).

  • Business Wire

    Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021

    NEW YORK & LONDON & PARIS, September 15, 2021--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021.